Septerna-Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule for Hypoparathyroidism, With Data Expected in Mid-2025
Septerna-Phase 1臨床試驗正在進行,針對Hypoparathyroidism的SEP-786口服小分子藥物,數據預計將於2025年中公佈
Septerna-Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule for Hypoparathyroidism, With Data Expected in Mid-2025
Septerna-Phase 1臨床試驗正在進行,針對Hypoparathyroidism的SEP-786口服小分子藥物,數據預計將於2025年中公佈
譯文內容由第三人軟體翻譯。